Nutex Health price target raised to $50 from $45 at Maxim

Maxim raised the firm’s price target on Nutex Health (NUTX) to $50 from $45 and keeps a Buy rating on the shares. The company’s Q3 results topped estimates, with positive trends in metrics fueling its growth, the analyst tells investors in a research note. Maxim adds that the firm expects Nutex to generate $8.9M in operating cash per quarter through 2025 and believes that the company has sufficient capital to maintain current operations, even though it may raise capital to accelerate new hospital openings.